{{--
  Back to User
--}}
{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode'])) Logout @endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
Back

A survey to assess perception of triple fixed dose combination of empagliflozin, sitagliptin and metformin in the various patient profiles of type 2 diabetes (ADVANCE-Survey)

Survey Questionnaire Form
Doctor's details
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif @if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif

Questionnaire
  1. Which among the below are common patient profiles as observed in your practice? (Multiple choice) *

  2. What are the major challenges in patients presenting with uncontrolled diabetes? *
  3. What is the HbA1c goal considered for Young (Age<50 years) T2DM patients in practice? *

  4. What is the HbA1c goal considered for Elderly (Age >65 yeas) T2DM patients in practice? *

  5. What is the HbA1c goal considered for T2DM patients with CVD or HF in practice? *

  6. What is the HbA1c goal considered for T2DM patients with CKD in practice? *

  7. What is the HbA1c goal considered for T2DM patients with obesity in practice? *

  8. Please share primary factors that determine different HbA1c goal in each patient profiles? *
  9. What percentage of patients with T2DM have history of CVD as observed in your practice? *

  10. What percentage of patients with T2DM have history of HF as observed in your practice? *

  11. What percentage of patients with T2DM have history of CKD as observed in your practice? *

  12. Do you consider risk of hypoglycaemia as a major determining factor in choice of OAD’s? *

  13. What is your preferred approach in treating patients with risk of hypoglycaemia? *
  14. Do you prefer triple fixed dose combinations in patients with risk of hypoglycaemia? What is you preferred triple FDC of OAD’s in patients with risk of hypoglycaemia? *
  15. Based on the literature shared do you consider the combination to have low risk of hypoglycaemia? *

  16. The burden of cardiovascular disease and diabetes is very high in our population, what is you preferred approach in treating these patients? *
  17. Guidelines suggest utilizing SGLT2i in T2DM patients with ASCVD and based on the literature shared Empagliflozin is effective in reduction of mortality and cardiovascular death in diabetic patients. Do you consider utilizing SGLT2i in these patients and what are the practical considerations to initiate SGLT2i in these patients? *
  18. About 67% of T2DM patients are uncontrolled according to the literature? What percentage of T2DM patients with ASCVD are uncontrolled in your practice? *

  19. Is hypoglycaemia a major concern in T2DM patients with ASCVD? *

  20. Is hypoglycaemia a major concern in T2DM patients with HF? *

  21. If hypoglycaemia is considered a major concern in patients with ASVD and CKD, what is the treatment goal in such patients? *

  22. What percentage of Diabetic patients develop CVD as observed in your practice? *

  23. What percentage of Diabetic patients develop CKD as observed in your practice? *

  24. What percentage of Diabetic patients develop metabolic impairment as observed in your practice? *

  25. What factors are involved in the worsening outcomes of T2DM *
  26. Considering the safety profile of all three components of the FDC, do you consider this combination in elderly? *
  27. Considering the safety profile of all three components of the FDC, do you consider this combination in frail patients? *
  28. Evidence suggest that SGLT2i cause reduction in weight while sitagliptin and metformin are weight neutral, based on the evidence shared do you consider this FDC of Empagliflozin, Sitagliptin and Metformin in T2DM patients with obesity? *

  29. Based on your observations in clinical practice what are the benefits of the triple combination of SGLT2i, DPP4i and Metformin? *
  30. In patients newly diagnosed with diabetes, when do you consider triple combination therapy? *
  31. Are all patients with T2DM at risk for cardiovascular complications? If no which patients are screened for the complications? *
  32. Are all patients with T2DM at risk for renal complications? If no which patients are screened for the complications? *
  33. Which among the below would you consider as benefit of the FDC of Empagliflozin, Sitagliptin and Metformin? (Multiple options) *

  34. Between Dapagliflozin and Empagliflozin which characteristics would you score higher for Empagliflozin? (Multiple Choice) *

  35. In patients with uncontrolled diabetes and HbA1c >9.0%, do you consider SGLT2i? *

  36. In lean patients with diabetes would you consider using the triple FDC of SGLTi, DPP4i and Metformin? *

  37. Which among the below is a concern in utilizing combination therapies with SGLT2i *

  38. Which of the below mentioned options do you consider high risk for development of Cardiorenal and metabolic syndrome? *

  39. What percentage T2DM patients have Cardiorenal and other metabolic impairments? *

  40. Based on your clinical experience please share suggestions to improve multipronged approach to address cardiorenal metabolic continuum? *